Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OLMA 
Olema Pharmaceuticals Inc (OLMA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: OLMA (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25
1 Year Target Price $25
| 5 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 67.85% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 541.52M USD | Price to earnings Ratio - | 1Y Target Price 25 |
Price to earnings Ratio - | 1Y Target Price 25 | ||
Volume (30-day avg) 8 | Beta 1.94 | 52 Weeks Range 2.86 - 13.93 | Updated Date 09/17/2025 |
52 Weeks Range 2.86 - 13.93 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.97 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.87% | Return on Equity (TTM) -49.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 184366855 | Price to Sales(TTM) - |
Enterprise Value 184366855 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.33 | Shares Outstanding 68634304 | Shares Floating 39645247 |
Shares Outstanding 68634304 | Shares Floating 39645247 | ||
Percent Insiders 3.31 | Percent Institutions 104.73 |
Upturn AI SWOT
Olema Pharmaceuticals Inc
Company Overview
History and Background
Olema Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of targeted therapies for women's cancers. Founded in 2018, Olema went public in 2020. It is focused on developing therapies targeting hormone-dependent cancers.
Core Business Areas
- Oncology Drug Development: Olema focuses on developing and commercializing therapies for women's cancers. Their lead product candidate is an estrogen receptor (ER) antagonist.
Leadership and Structure
Sean P. Bohen, M.D., Ph.D., is the President and CEO. The company operates with a structure typical for a clinical-stage biopharmaceutical company, focusing on research & development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- OPC-51803 (Palazestrant): Palazestrant is Olema's lead product candidate, a complete estrogen receptor antagonist (CERAN) being developed for ER-positive, HER2-negative metastatic breast cancer. It is currently in clinical trials. As a clinical stage company, Olema currently has no revenue from product sales. Competitors include companies developing other SERDs/CERANs such as Menarini Group (Elacestrant/Orserdu), Radius Health (elacestrant), and Sanofi (amcenestrant, discontinued development).
Market Dynamics
Industry Overview
The oncology market is a large and growing market, driven by an aging population and increasing cancer incidence. Significant research and development are ongoing for breast cancer therapeutics.
Positioning
Olema aims to address unmet needs in ER-positive, HER2-negative breast cancer with its CERAN, potentially offering advantages over existing therapies that may have limited efficacy or tolerability challenges.
Total Addressable Market (TAM)
The TAM for ER-positive, HER2-negative breast cancer therapeutics is substantial. Olema is targeting a segment of patients who have progressed on prior endocrine therapies, estimated to be several billion dollars. Olema's potential position in this TAM depends on clinical trial success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel CERAN mechanism of action
- Experienced management team
- Strong financial position (after IPO)
- Focus on a specific, well-defined patient population
Weaknesses
- Clinical-stage company with no approved products
- Reliance on a single lead product candidate
- High risk of clinical trial failure
- Limited commercial infrastructure
Opportunities
- Successful clinical trial results leading to regulatory approval
- Expansion into other ER-positive cancer indications
- Potential for partnerships with larger pharmaceutical companies
- Growing market for targeted cancer therapies
Threats
- Clinical trial failure
- Competition from existing and emerging therapies
- Regulatory hurdles
- Patent challenges
- Difficulties in commercialization
Competitors and Market Share
Key Competitors
- SNY (Sanofi)
- RDUS (Radius Health)
- MNKKQ (Menarini Group, not publicly traded in the US)
Competitive Landscape
Olema's advantage is its novel CERAN mechanism. Disadvantages include its clinical stage and dependence on a single asset. Sanofi, Radius Health, and Menarini have already approved SERDs and significant resources.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily defined by the advancement of its lead product candidate through clinical trials.
Future Projections: Future growth depends on the success of clinical trials and potential regulatory approval of Palazestrant. Analyst estimates will vary depending on perceived probability of success.
Recent Initiatives: Focus on ongoing clinical trials for Palazestrant in ER-positive, HER2-negative metastatic breast cancer.
Summary
Olema is a clinical-stage biotech with a promising lead candidate in a significant market. Its success is tied to clinical trial outcomes, making it a high-risk, high-reward investment. The company faces competition from established players and other emerging therapies and needs to be mindful of regulatory hurdles and cash runway.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Olema Pharmaceuticals Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Olema Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2020-11-19 | President, CEO & Director Dr. Sean P. Bohen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 116 | Website https://olema.com |
Full time employees 116 | Website https://olema.com | ||
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.